STOCK TITAN
  1. Home
  2. Sec-filings
  3. TEVA
  4. [Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Teva (NYSE: TEVA) EVP sells 128,985 shares after RSU vesting

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD executive Richard Daniell, EVP, Europe Commercial, reported exercising restricted share units and related share sales. On March 3, 2026, he converted restricted share units into ordinary shares at a price of $0.0000 per share through multiple derivative exercises.

He then sold a total of 128,985 ordinary shares in open-market transactions at a weighted average price of $32.3599 per share, with actual prices ranging from $31.72 to $32.865. These sales were made under a Rule 10b5-1 trading plan adopted on November 10, 2025 and include shares sold to cover tax withholding obligations tied to RSU vesting and performance-based awards. Following these transactions, he directly held 123,127 ordinary shares, and certain restricted share units continue to vest, including tranches through March 4, 2027.

Positive

  • None.

Negative

  • None.
Insider Daniell Richard
Role EVP, Europe Commercial
Sold 128,985 shs ($4.17M)
Type Security Shares Price Value
Exercise Restricted Share Units 62,250 $0.00 --
Exercise Restricted Share Units 141,478 $0.00 --
Exercise Ordinary Shares 62,250 $0.00 --
Sale Ordinary Shares 62,250 $32.3599 $2.01M
Exercise Ordinary Shares 141,478 $0.00 --
Sale Ordinary Shares 66,735 $32.3599 $2.16M
Holdings After Transaction: Restricted Share Units — 62,253 shares (Direct); Ordinary Shares — 110,634 shares (Direct)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 3, 2023, with 62,250 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 4, 2027. Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Daniell Richard
(Last) (First) (Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
(Street)
TEL AVIV L3 6944020
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Europe Commercial
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 03/03/2026 M 62,250 A (2) 110,634 D
Ordinary Shares(1) 03/03/2026 S(3) 62,250(4) D $32.3599(5) 48,384 D
Ordinary Shares(1) 03/03/2026 M 141,478 A (2) 189,862 D
Ordinary Shares(1) 03/03/2026 S(3) 66,735(4) D $32.3599(5) 123,127 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units (2) 03/03/2026 M 62,250 (6) (6) Ordinary Shares(1) 62,250 $0 62,253 D
Restricted Share Units (2) 03/03/2026 M 141,478 (7) (7) Ordinary Shares(1) 141,478 $0 0 D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
4. Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
6. Restricted share units were granted on March 3, 2023, with 62,250 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 4, 2027.
7. Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Teva (TEVA) EVP Richard Daniell report?

Richard Daniell reported exercising restricted share units into ordinary shares and then selling 128,985 Teva ordinary shares on March 3, 2026. The transactions combined derivative exercises at $0.0000 per share with open-market sales at a weighted average of $32.3599.

How many Teva (TEVA) shares did Richard Daniell sell and at what prices?

He sold a total of 128,985 ordinary shares in two open-market transactions on March 3, 2026. The weighted average sale price was $32.3599 per share, with individual trades executed between $31.72 and $32.865, inclusive.

Were Richard Daniell’s Teva (TEVA) share sales under a Rule 10b5-1 plan?

Yes, the reported sales were effected under a Rule 10b5-1 trading plan adopted by Richard Daniell on November 10, 2025. Such plans pre-schedule trades, allowing insiders to sell shares over time according to predefined instructions.

How are Richard Daniell’s Teva (TEVA) restricted share units structured?

Each restricted share unit gives a contingent right to receive one ordinary share or its cash value at settlement. One grant from March 3, 2023 vests in annual tranches, including 62,253 units scheduled to vest on March 4, 2027.

What performance-based Teva (TEVA) restricted units did Richard Daniell earn?

Certain restricted share units subject to performance criteria were earned on January 27, 2026 after committee certification. These units subsequently vested on March 3, 2026 once time-based conditions were satisfied, leading to share issuances and related tax-withholding sales.

How many Teva (TEVA) shares does Richard Daniell hold after these transactions?

After the March 3, 2026 exercises and sales, Richard Daniell directly held 123,127 Teva ordinary shares. This figure reflects completed derivative conversions, open-market sales, and remaining directly owned shares reported in the Form 4 filing.

Why were some of Richard Daniell’s Teva (TEVA) shares sold upon RSU vesting?

The filing states that shares were sold to cover tax withholding obligations tied to RSU vesting and performance-based awards. In such cases, a portion of newly vested shares is sold to satisfy tax liabilities triggered at vesting.